CytoDyn $CYDY mit Blockbuster Potential WKN: A0YHA5 (Seite 2062)

[sunny3999]

Anthony ex-Geschäftsführer einer großen Klinikkette berichtet von einem Arzt zu Leron vs Remdesevir!

Er ist aktiv unterwegs und überzeugt Nationale Reporter, Verantwortliche aus der Gesundheitsversicherungsbranche und Klinikärzte. Anthony ist in Gold nicht aufzuwiegen, was er alles für Cytodyn als quasi Rentner alles bewegt! Respekt...der dreht an den großen Rädern um zu überzeugen!

Anthony3 hours ago
Here is an email one of my MD pulmonologist friends sent that reporter. I hope you will agree that this is very thoughtful and well done. I would love to jam this up some of the arrogant posters on Seeking Alpha, but am not going to post it over there. Here goes:

Good afternoon to you both

Sorry for the delayed response. Busy day in the world of medicine and so not had a chance to respond earlier. Here are a few high level thoughts for consideration as I put on my scientific hat. As a disclaimer, I am not expert in infectious disease or virology and I do own shares of Cytodyne Corporation. However, as an academic and practicing pulmonary critical care physician, I have been actively following the medical literature and science as it relates to both Leronlimab and Remdesivir. Further, I have several years of pharmaceutical drug development and am still actively consulting as a safety officer within drug development which does limit what I can say publicly. However, happy to discuss further after you have had a chance to digest the following observations/ comments.

Differing mechanisms of action as well as a differing safety profile warranting. There may be utility in both agents in the management of COVID-19. However, in my assessment there may be more robust clinical data in support of Leronlimab relative to that of Remdesivir. As reported in the Lancet, a randomized double blind, placebo controlled, multicenter trial, 237 patients were enrolled and randomly assigned to a treatment group of either remdesivir vs. placebo. Remdesivir was not associated with statistically significant clinical benefit. However, there was a numerical reduction in time to clinical improvement in those treated earlier. As will be discussed momentarily, this may suggest that he use of Remdesivir may be better positioned earlier in the course of a viral infectio. In contrast, Leronlimab may be efficacious throughtout the course of an active viral infection.

Notably, Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early. Interestingly, some 60% reported adverse events, including elevated hepatic enzymes, diarrhea, rash, renal impairment, and hypotension in the patients given Remdesevir. In contrast, the side effect profile of Leronlimab included only diarrhea, headache, swollen lymph nodes, high blood pressure and injection site reactions. Noticeably absent are hepatic enzyme elevations and renal impairment in the case of Leronlimab. To my knowledge, in over nine clinical trials with more than 800 patients treated Leronlimab , there were no drug-related serious adverse events (AEs), serious adverse events (SAEs), or dose-limiting toxicities among participants were reported in clinical studies

Data here in the US is limited and based on 61 patients hospitalized with confirmed COVID-19. These patients were not randomized and thus no control arm which does not provide the same degree of scientific rigor. Importantly, eight patients were excluded from the final analysis, largely because of missing data which raises some concerns from a safety and efficacy reporting standpoint as it relates to Remdesivir. Thus, there does appear to be a potential safety profile difference between these two agents, but needs to be elucidated thru more rigorous clinical trials. There are fewer patients with COVID-19 that have been treated with Leronlimab but early results are encouraging as well and I may be mistaken, but I believe this was a sicker population of patients as well.

Mechanistically, Remdesivir is a nucleoside analogue and so functions to inhibit viral replication. Yet, in the lancet article, authors noted that Remdesivir did not result in significant reductions in SARS-CoV-2 RNA loads or detectability in upper respiratory tract or sputum specimens in this study despite showing strong antiviral effects in preclinical models of infection with coronaviruses. This goes back to my earlier supposition as to the time of administration as it relates to the efficacy of Remdesivir. This is mirrored by what we are seeing in the commercial use of antiviral therapy for influenza A and B in which there is a window of opportunity. In contrast, Leronlimab is humanized monoclonal IgG antibody that works by blocking intracellular immune signaling mechanisms whih play a role in viral entry but that have been associated with a dysregulated immune response leading to what is often described clinically as a cytokine storm. Severe cytokine storm leads to markedly higher levels of pro-inflammatory cytokines and has been detected in patients hospitalized with severe influenza infections and similarly in COVID-19 patients Thus, I would suggest that there may be a broader therapeutic window for the use of Leronlimab.

Much to be learned still about COVID-19 as it relates to its pathophysiogy and treatment, but Leronlimab appears to have a robust safe!

[aldy78]

Antwort auf Beitrag Nr.: 63.649.942 von sunny3999 am 12.05.20 17:50:51

Jetzt darf aber dann langsam mal ne ordentlich positive Reaktion kommen bei CyToDyn ... 🧘‍♂️🤪

[sunny3999]

Pharmacy Times zu Leronlimab: Neuartiges Medikament kann Entzündungen bei kritischen COVID-19-Patienten reduzieren

2020-05-12 13:39:00
Jill Murphy, Redaktionsassistentin
Übersetzung:
https://translate.google.com/translate?hl=de&sl=en&u=https://www.pharmacytimes.com/news/novel-drug-may-reduce-inflammation-in-critical-covid-19-patients&prev=search

Original:
Novel Drug May Reduce Inflammation in Critical COVID-19 Patients
https://www.pharmacytimes.com/news/novel-drug-may-reduce-inf…

[tippse]

Antwort auf Beitrag Nr.: 63.648.091 von DWL33 am 12.05.20 15:48:14

dann hoffen wir mal, dass das NIH auch leronlimab bald auf dem Schirm hat!

https://www.nih.gov/news-events/news-releases/nih-launch-pub…

[tippse]

Antwort auf Beitrag Nr.: 63.648.256 von StellaVella am 12.05.20 15:58:20

scheinen dazuzulernen:

These include studies on therapies such as antiviral drugs to keep viruses from multiplying, as well as therapies called immunomodulators aimed at tamping down the body’s own immune reaction to the virus, in cases where the body starts attacking the patient’s own organs.

siehe link von just_fish

[just_fish]

https://www.fda.gov/news-events/press-announcements/coronavi…

[swoasik]

Antwort auf Beitrag Nr.: 63.647.371 von tippse am 12.05.20 15:02:31

Ein guter CEO macht den Wirkstoff nicht besser , sondern evtl Interessanter !
Aber ein schlechter CEO macht einen guten Wirkstoff nicht schlechter , oder gar unwirksam!!
Gruß

[Rolf1K]

Was haltet ihr von Nanoviricides? Geht gerade um 36% hoch. In Invitro-Studien war ihr Medi viel effektiver als Remdesivir und Favipravir von Fujifilm. Es hat angeblich den Virus "wie eine Venusfalle die Fliegen" gefangen.
Ich will nicht verkaufen, habe aber noch etwas Geld frei.

[StellaVella]

Antwort auf Beitrag Nr.: 63.648.091 von DWL33 am 12.05.20 15:48:14

J Lalezari hat da einen Hinweis gegeben, in dem von Sunny geteilten Interview.
Die FDA war wegen des MOAs von Leronlimab zu Beginn der Corona-Krise skeptisch, ob Leronlimab überhaupt etwas bewirken kann bei COVID19 und hat deshalb Leronlimab von der Priorität her tief eingestuft ("backburner" war der Ausdruck, den Lalezari verwendet hat). Stattdessen haben sie sich gemäß JL auf Antivirals konzentriert.

Ich denke um so wichtiger muss man Pattersons Entdeckung, dass es sich bei COVID19 um eine Rantes-Erkrankung handelt, einstufen. Insofern ist die hoffentlich bald erfolgende Publikation ein wichtiges Argument PRO Leronlimab und hilft bei Diskussionen mit der FDA.

[tippse]

Antwort auf Beitrag Nr.: 63.648.091 von DWL33 am 12.05.20 15:48:14

Sehe ich auf der medizinischen Seite genauso (zumindest machen sie mir als Laie hier ein äußerst seriösen Eindruck) - ich meine die Business-Seite.